Navigation Links
Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
Date:4/3/2011

BASKING RIDGE, N.J., April 3, 2011 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced today the primary results of the RADAR Phase 2b clinical trial of the company's lead product, the anticoagulation system REG1, at the i2 Summit during the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans, LA.  REG1 is a two-component system consisting of pegnivacogin, a highly selective Factor IXa (FIXa) inhibitor and anivamersen, its complementary specific active control agent.

The presentation, "A Randomized, Partially-Blinded, Multi-Center, Active-Controlled, Dose-ranging Study Assessing the Safety, Efficacy and Pharmacodynamics of the REG1 Anticoagulation System Compared to Unfractionated Heparin or Low Molecular Weight Heparin in Subjects with Acute Coronary Syndromes: Primary Results of the RADAR Randomized Clinical Trial," was made by Thomas J. Povsic, MD, PhD, Assistant Professor of Medicine at Duke University during an i2 Special Session titled "Interventional Featured Clinical Studies I."  

The international Phase 2b RADAR clinical trial was conducted in subjects admitted for ACS-unstable angina and myocardial infarction without ST-segment elevation (UA/NSTEMI) intended for cardiac catheterization within 24 hours.  The objectives of RADAR were to verify that 1 mg/kg of pegnivacogin resulted in near complete FIXa inhibition, to determine the dose of anivamersen which, when followed by immediate arterial sheath removal, results in a bleeding rate lower than heparin and to assess the efficacy of REG1 (based on ischemic event rates) as an anticoagulant system in an invasively managed ACS population.  The primary endpoint of the study was ACUITY bleeding (major and minor) at 30 days.  A secondary endpoint was
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
2. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
3. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
4. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
5. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
6. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
7. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
8. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
9. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
10. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
11. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3, 2015 Research and Markets ... "Radiology Information Systems Market by Type, Deployment Mode, ... Forecast to 2019" report to their offering. ... estimated at $501.1 Million 2014, and is projected to ... 7.6% from 2014 to 2019. The ...
(Date:9/3/2015)... , Sept. 3, 2015 HeartWare ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that its President and Chief Executive Officer, ... 2015 Wells Fargo Healthcare Conference at 8:50 a.m. ET ... Sept. 9-10, 2015 at The Hyatt Regency, ...
(Date:9/3/2015)... 3, 2015  Four financial reasons to reduce ... paper released by Leaf Healthcare, Inc . ... & Quality (AHRQ), pressure ulcers cost the ... . In addition to direct treatment related costs, ... and negatively impact hospital performance metrics. On top ...
Breaking Medicine Technology:Radiology Information Systems Market Report 2015 - Global Trends & Forecast to 2019 for the $700+ Million Industry 2Radiology Information Systems Market Report 2015 - Global Trends & Forecast to 2019 for the $700+ Million Industry 3HeartWare Presentation At The 2015 Wells Fargo Healthcare Conference To Be Webcast 2Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 2Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 3
... Bolder BioTechnology, Inc. today announced that it has ... (SBIR) grant totaling $600,000 from the National Institute of ... of Health (NIH).  The grant will be used to ... analog to accelerate platelet recovery and improve survival in ...
... Technologies Foster Better Informed Consumers, Greater Interest in Personal... -- PHILADELPHIA, Pennsylvania, August 18, 2010 ... ... lpUnit=,PRN,; --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
Cached Medicine Technology:Bolder BioTechnology Announces $600,000 Grant from NIH to Study Long-Acting IL-11 Analog in Treating Acute Radiation Syndrome 2Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 2Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 3Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 4Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 5Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 6Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 7Advanced Web-Based Medical Technologies Foster Better Informed Consumers, Greater Interest in Personal Health Care 8
(Date:9/3/2015)... ... September 03, 2015 , ... ... treatment for adults and adolescents struggling with anorexia, bulimia, binge eating disorder ... medical treatment team. As a Staff Psychiatrist, Dr. Calinoiu collaborates closely with ...
(Date:9/3/2015)... ... September 03, 2015 , ... Global Vision , the world leader ... spotlighting its award-winning print and artwork inspection solutions, ScanProof and ArtProof at ... at the Olympia London, booth #F33 , Be the first to get a sneak ...
(Date:9/3/2015)... ... September 03, 2015 , ... Hunters Creek Retrievers ... with a champion AKC Black Lab Puppy. Celebrate Fall 2015 with unlimited Free Hugs ... and family to enjoy Thanksgiving and Christmas with an extra big smile. , ...
(Date:9/3/2015)... ... ... A scar is an unavoidable result of incision or injury to the skin. Unsightly as ... itself. The appearance of a scar is dependent on many factors – the size and ... scars fade to near invisibility on their own over a period of months,” says ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... will be participating at the highly anticipated Mississippi Gulf Babypalooza on September 19, ... from all over, from Gulfport, Biloxi, and beyond. We will be discussing setting ...
Breaking Medicine News(10 mins):Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 2Health News:Ileana Calinoiu, MD Joins Eating Recovery Center of Washington Medical Treatment Team 3Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2
... to a recent IOM report, only 6 percent of ... care for children. With high rates of novel H1N1 ... these deficiencies is immediate. , In a joint ... Care of Children in the Emergency Department," pediatric emergency ...
... have ample evidence that individuals use a variety of cues ... in families other than their own. A new study shows ... or not those families are the same race as themselves. ... Journal of Vision ("Cross-cultural perceptions of facial resemblance between ...
... , , NEW YORK, Sept. 21 ... first impression. The fall season ushers in many first encounters, from the ... Looking and feeling your best will help you exude confidence, so follow ... To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/crest/39172/ ...
... September 21 Health Robotics today,announced that it ... Technologies Australia Pty Ltd. for its revolutionary,CytoCare(TM) Robot. ... its goal of safely, accurately and cost-effectively,automating the ... market-leading Oncology and Surgery Robotic solutions. , ...
... 21 /PRNewswire-FirstCall/ - Equity Capital Management (ECM) ... review of the HTDS business model. ECM ... HTDS followers at the following link ... (ECM) believes that in the current economic ...
... ... TCO by Streamlining IT Audit Processes, Harmonizing Controls with Policy Requirements, and Providing Greater IT ... ... , , ,News Facts:, , ,A typical organization spends 30-50% more on compliance and IT ...
Cached Medicine News:Health News:Race has little effect on people's ability to spot family resemblances 2Health News:Photos: Fall's First Impressions 2Health News:Health Robotics Continues Global Expansion Into Oceania With Device Technologies Australia's Strategic Partnership 2Health News:Health Robotics Continues Global Expansion Into Oceania With Device Technologies Australia's Strategic Partnership 3Health News:Equity Capital Management H1N1 Vaccines and Hard to Treat Diseases (HTDS) 2Health News:Lumension Unveils Enhanced Compliance and IT Risk Management Solution that Enables Organizations to Continuously Monitor Compliance and IT Risk Posture while Reducing the Overall Cost of Compliance 2Health News:Lumension Unveils Enhanced Compliance and IT Risk Management Solution that Enables Organizations to Continuously Monitor Compliance and IT Risk Posture while Reducing the Overall Cost of Compliance 3Health News:Lumension Unveils Enhanced Compliance and IT Risk Management Solution that Enables Organizations to Continuously Monitor Compliance and IT Risk Posture while Reducing the Overall Cost of Compliance 4Health News:Lumension Unveils Enhanced Compliance and IT Risk Management Solution that Enables Organizations to Continuously Monitor Compliance and IT Risk Posture while Reducing the Overall Cost of Compliance 5Health News:Lumension Unveils Enhanced Compliance and IT Risk Management Solution that Enables Organizations to Continuously Monitor Compliance and IT Risk Posture while Reducing the Overall Cost of Compliance 6Health News:Lumension Unveils Enhanced Compliance and IT Risk Management Solution that Enables Organizations to Continuously Monitor Compliance and IT Risk Posture while Reducing the Overall Cost of Compliance 7
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: